Afinitor/Afinitor Disperz (everolimus)(3)

Contraindicated in patients with clinically significant hypersensitivity to everolimus or to other rapamycin derivatives.

Akeega (niraparib and abiraterone)(114)

None

Alecensa (alectinib)(4)

None

Alunbrig (brigatinib)(5)

None

Augtyro (repotrectinib)(118)

None

Ayvakit (avapritinib)(6)

None

Balversa (erdafitinib)(7)

None

BESREMi (ropeginterferon alfa-2b-njft)(8)

BESREMi has a boxed warning for risk of serious disorders:

• Interferon alfa products may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping therapy.

BESREMi is contraindicated in patients with:

• Existence of, or history of severe psychiatric disorders, particularly severe depression, suicidal ideation, or suicide attempt.
• Hypersensitivity to interferons including interferon alfa-2b or any of the inactive ingredients of BESREMi.
• Moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
• History or presence of active serious or untreated autoimmune disease.
• History of transplantation and receiving immunosuppressant agents.

Bosulif (bosutinib)(9)

Contraindicated in patients with a history of hypersensitivity to bosutinib.

Braftovi (encorafenib)(10)

None

Brukinsa (zanubrutinib)(11)

None

Cabometyx (cabozantinib)(12)

None

Calquence (acalabrutinib)(13)

None

Caprelsa (vandetanib)(14)

Caprelsa has a boxed warning for QT prolongation, torsades de pointes, and sudden death:

• Caprelsa can prolong the QT interval. Torsades de pointes and sudden death have occurred in patients receiving Caprelsa. Do not use Caprelsa in patients with hypocalcemia, hypokalemia, hypomagnesemia, or long QT syndrome. Correct hypocalcemia, hypokalemia and/or hypomagnesemia prior to Caprelsa administration. Monitor electrolytes periodically. Avoid drugs known to prolong the QT interval. 

Contraindicated in patients with congenital long QT syndrome.

Cometriq (cabozantinib)(15)

None

Copiktra (duvelisib)(16)

Copiktra has a boxed warning for treatment-related mortality and serious toxicities: infections, diarrhea or colitis, cutaneous reactions, and pneumonitis:

• Treatment-related mortality occurred in 15% of Copiktra-treated patients.
• Fatal and/or serious infections occurred in 31% of Copiktra-treated patients. Monitor for signs and symptoms of infection. Withhold Copiktra if infection is suspected.
• Fatal and/or serious diarrhea or colitis occurred in 18% of Copiktra-treated patients. Monitor for the development of severe diarrhea or colitis. Withhold Copiktra.
• Fatal and/or serious cutaneous reactions occurred in 5% of Copiktra-treated patients. Withhold Copiktra. 
• Fatal and/or serious pneumonitis occurred in 5% of COPIKTRA-treated patients. Monitor for pulmonary symptoms and interstitial infiltrates. Withhold Copiktra.

Copiktra has no contraindications of use. 

Cotellic (cobimetinib)(17)

None

Daurismo (glasdegib)(18)

Daurismo has a boxed warning for embryo-fetal toxicity: 

• Daurismo can cause embryo-fetal death or severe birth defects when administered to a pregnant woman. Daurismo is embryotoxic, fetotoxic, and teratogenic in animals.
• Conduct pregnancy testing in females of reproductive potential prior to initiation of Daurismo treatment. Advise females of reproductive potential to use effective contraception during treatment with Daurismo and for at least 30 days after the last dose.
• Advise males of the potential risk of Daurismo exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential during treatment with Daurismo and for at least 30 days after the last dose to avoid potential drug exposure.

Daurismo has no contraindications of use. 

Erivedge (vismodegib)(19)

Erivedge has a boxed warning for embryo-fetal toxicity:

• Erivedge can cause embryo-fetal death or severe birth defects when administered to a pregnant woman. Erivedge is embryotoxic, fetotoxic, and teratogenic in animals. Teratogenic effects included severe midline defects, missing digits, and other irreversible malformations.
• Verify the pregnancy status of females of reproductive potential within 7 days prior to initiating Erivedge. Advise pregnant women of the potential risks to a fetus. Advise females of reproductive potential to use effective contraception during and after Erivedge.
• Advise males of the potential risk of Erivedge exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential.

Erivedge has no contraindications of use. 

Erleada (apalutamide)(20)

None

Fotivda (tivozanib)(23)

None

Fruzaqla (fruquintinib)(116)

None

Gavreto (pralsetinib)(24)

None

Gilotrif (afatinib)(25)

None

Gleevec (imatinib)(26)

None

Hycamtin (topotecan)(27)

Hycamtin has a boxed warning for myelosuppression:

• Hycamtin can cause severe myelosuppression. Administer first cycle only to patients with baseline neutrophil counts of greater than or equal to 1,500/mm^3 and platelet counts greater than or equal to 100,000/mm^3. Monitor blood cell counts.

Contraindicated in patients with a history of severe hypersensitivity to topotecan.

Ibrance (palbociclib)(28)

None

Iclusig (ponatinib)(29)

Iclusig has a boxed warning for arterial occlusive events, venous thromboembolic events (VTE), heart failure, and hepatotoxicity:

• Arterial occlusive events (AOEs), including fatalities, have occurred in Iclusig-treated patients. AOEs included fatal myocardial infarction, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, and the need for urgent revascularization procedures. Patients with and without cardiovascular risk factors, including patients age 50 years or younger, experienced these events. Monitor for evidence of AOEs. Interrupt or discontinue Iclusig based on severity.
• VTEs have occurred in Iclusig-treated patients. Monitor for evidence of VTEs. Interrupt or discontinue Iclusig based on severity.
• Heart failure, including fatalities, occurred in Iclusig-treated patients. Monitor for heart failure and manage patients as clinically indicated. Interrupt or discontinue Iclusig for new or worsening heart failure.
• Hepatotoxicity, liver failure and death have occurred in Iclusig-treated patients. Monitor liver function tests. Interrupt or discontinue Iclusig based on severity.

Iclusig has no contraindications of use. 

Idhifa (enasidenib)(30)

Idhifa has a boxed warning for differentiation syndrome:

• Patients treated with Idhifa have experienced symptoms of differentiation syndrome, which can be fatal if not treated. Symptoms may include fever, dyspnea, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, lymphadenopathy, bone pain, and hepatic, renal, or multi-organ dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.

Idhifa has no contraindications of use. 

Imbruvica (ibrutinib)(31)

None

Inlyta (axitinib)(32)

None

Inqovi (decitabine/ cedazuridine)(33)

None

Inrebic (fedratinib)(34)

Inrebic has a boxed warning for encephalopathy including Wernicke's: 

• Serious and fatal encephalopathy, including Wernicke's, has occurred in patients treated with Inrebic. Wernicke's encephalopathy is a neurologic emergency. Assess thiamine levels in all patients prior to starting Inrebic, periodically during treatment, and as clinically indicated. Do not start Inrebic in patients with thiamine deficiency; replete thiamine prior to treatment initiation. If encephalopathy is suspected, immediately discontinue Inrebic and initiate parenteral thiamine. Monitor until symptoms resolve or improve and thiamine levels normalize. 

Inrebic has no contraindications of use. 

Iressa (gefitinib)(35)

None

Iwilfin (eflornithine)(120)

None

Jakafi (ruxolitinib)(36)

None

Jaypirca (pirtobrutinib)(110) 

None

Kisqali (ribociclib)(38)

None

Kisqali Femara Pack (ribociclib and letrozole co-packaged)(37)

Contraindicated in patients with known hypersensitivity to letrozole or any excipients of Femara.

Koselugo (selumetinib)(39)

None

Krazati (adagrasib)(109)

None

Lazcluze (lazertinib)(2)

None

Lenvima (lenvatinib)(40)

None

Lonsurf (trifluridine/tipiracil)(41)

None

Lorbrena (lorlatinib)(42)

Contraindicated in concomitant use with a strong CYP3A inducer, due to potential for serious hepatotoxicity.

Lumakras (sotorasib)(43)

None

Lynparza (olaparib)(44)

None

Lysodren (mitotane)(45)

Lysodren has a boxed warning for adrenal crisis in the setting of shock, severe trauma or infection:

• Patients treated with Lysodren are at increased risk for developing adrenal crisis in the setting of shock, severe trauma or infection that may lead to death.
• If shock, severe trauma or infection occurs or develops, temporarily discontinue Lysodren and administer exogenous steroids. Monitor patients closely for infections and instruct patients to contact their physician immediately if injury, infection, or any other concomitant illness occurs.

Lysodren has no contraindications of use. 

Lytgobi (futibatinib)(107)

None

Matulane (procarbazine)(46)

Matulane has a boxed warning that recommends that Matulane be given only by or under the supervision of a physician experienced in the use of potent antineoplastic drugs. Adequate clinical and laboratory facilities should be available to patients for proper monitoring of treatment. 

Contraindicated in patients with known hypersensitivity to the drug or inadequate marrow reserve as demonstrated by bone marrow aspiration. 

Mekinist (trametinib)(47)

None

Mektovi (binimetinib)(48)

None

Nerlynx (neratinib)(49)

None

Nexavar (sorafenib)(50)

Contraindicated in the following:

• Patients with known severe hypersensitivity to sorafenib or any other component of Nexavar.
• Combination with carboplatin and paclitaxel in patients with squamous cell lung cancer.

Ninlaro (ixazomib)(51)

None

Nubeqa (darolutamide)(52)

None

Odomzo (sonidegib)(53)

Odomzo has a boxed warning for embryo-fetal toxicity: 

• Odomzo can cause embryo-fetal death or severe birth defects when administered to a pregnant woman. Odomzo is embryotoxic, fetotoxic, and teratogenic in animals.
• Verify the pregnancy status of females of reproductive potential prior to initiating therapy. Advise females of reproductive potential to use effective contraception during treatment with Odomzo and for at least 20 months after the last dose.
• Advise males of the potential risk of exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential during treatment with Odomzo and for at least 8 months after the last dose. 

Odomzo has no contraindications of use. 

Ogsiveo (nirogacestat)(119)

None

Ojemda (tovorafenib)(121)

None

Ojjaara (momelotinib)(115)

None

Onureg (azacitidine)(54)

Contraindicated in patients with history of severe hypersensitivity to azacitidine or its components. 

Orgovyx (relugolix)(55)

Contraindicated in patients with known severe hypersensitivity to relugolix or to any of the product components.

Orserdu (elacestrant)(111)

None

Pemazyre (pemigatinib)(56)

None

Piqray (alpelisib)(57)

Contraindicated in patients with a severe hypersensitivity to Piqray or to any of its components.

Pomalyst (pomalidomide)(58)

Pomalyst has a boxed warning for embryo-fetal toxicity and venous and arterial thromboembolism:

• Pomalyst is contraindicated in pregnancy. Pomalyst is a thalidomide analogue. Thalidomide is a known human teratogen that causes severe birth defects or embryo-fetal death. In females of reproductive potential, obtain 2 negative pregnancy tests before starting Pomalyst treatment.
• Deep venous thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke occur in patients with multiple myeloma treated with Pomalyst. Prophylactic antithrombotic measures were employed in clinical trials. Thromboprophylaxis is recommended, and the choice of regimen should be based on assessment of the patient's underlying risk factors.

Pomalyst is only available through a restricted distribution program called the Pomalyst REMS.

Contraindicated in patients who have demonstrated severe hypersensitivity (e.g., angioedema, anaphylaxis) to pomalidomide or any of the excipients.

Qinlock (ripretinib)(59)

None

Retevmo (selpercatinib)(60)

None

Revlimid (lenalidomide)(61)

Revlimid has a boxed warning for embryo-fetal toxicity, hematologic toxicity, and venous and arterial thromboembolism:

• Do not use Revlimid during pregnancy. Lenalidomide, a thalidomide analogue, caused limb abnormalities in a developmental monkey study. Thalidomide is a known human teratogen that causes severe life-threatening human birth defects. If lenalidomide is used during pregnancy, it may cause birth defects or embryo-fetal death.
• Revlimid can cause significant neutropenia and thrombocytopenia.
• Revlimid has demonstrated a significantly increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as risk of myocardial infarction and stroke in patients with multiple myeloma who were treated with Revlimid and dexamethasone therapy.

Contraindicated in patients with severe hypersensitivity to lenalidomide. 

Contraindicated in pregnancy and can cause fetal harm when administered to a pregnant female.

Rezlidhia (olutasidenib)(108)

Rezlidhia has a boxed warning for differentiation syndrome:

• Differentiation syndrome, which can be fatal, can occur with Rezlidhia treatment. Symptoms may include dyspnea, pulmonary infiltrates/pleuropericardial effusion, kidney injury, hypotension, fever, and weight gain.
• If differentiation syndrome is suspected, withhold Rezlidhia and initiate treatment with corticosteroids and hemodynamic monitoring until symptom resolution. 

Rezlidhia has no contraindications of use. 

Rozlytrek (entrectinib)(62)

None

Rubraca (rucaparib)(63)

None

Rydapt (midostaurin)(64)

Contraindicated in patients with hypersensitivity to midostaurin or any of the excipients.

Scemblix (asciminib)(65)

None

Sprycel (dasatinib)(66)

None

Stivarga (regorafenib)(67)

Stivarga has a boxed warning for hepatotoxicity:

• Severe and sometimes fatal hepatotoxicity has occurred in clinical trials.
• Monitor hepatic function prior to and during treatment.
• Interrupt and then reduce or discontinue Stivarga for hepatotoxicity as manifested by elevated liver function tests or hepatocellular necrosis, depending upon severity and persistence. 

Stivarga has no contraindications of use. 

Sutent (sunitinib)(68)

Sutent has a boxed warning for hepatotoxicity:

• Hepatotoxicity may be severe, and in some cases, fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue Sutent as recommended. 

Sutent has no contraindications of use. 

Tabrecta (capmatinib)(69)

None

Tafinlar (dabrafenib)(70)

None

Tagrisso (osimertinib)(71)

None

Talzenna (talazoparib)(72)

None

Tarceva (erlotinib)(73)

None

Targretin (bexarotene) 
capsules(74) 

Targretin capsules has a boxed warning for birth defects: 

• It is a member of the retinoid class of drugs that is associated with birth defects in humans. Targretin must not be administered to a pregnant woman.

Contraindicated in the following:

• Pregnancy. Targretin can cause fetal harm when administered to a pregnant female. 
• Patients with a known serious hypersensitivity to bexarotene or other components of the product.

Targretin (bexarotene) gel(75)

Contraindicated in the following:

• Pregnancy. Targretin can cause fetal harm when administered to a pregnant female. 
• Patients with known hypersensitivity to bexarotene or other components of the product.

Tasigna (nilotinib)(76)

Tasigna has a boxed warning for QT prolongation and sudden death:

• Tasigna prolongs the QT interval. Prior to Tasigna administration and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies. Obtain ECGs to monitor the QTc at baseline, seven days after initiation, and periodically thereafter, and following any dose adjustments.
• Sudden deaths have been reported in patients receiving Tasigna. Do not administer Tasigna to patients with hypokalemia, hypomagnesemia, or long QT syndrome.
• Avoid use of concomitant drugs known to prolong the QT interval and strong CYP3A4 inhibitors. Avoid food 2 hours before and 1 hour after taking the dose.

Contraindicated in patients with known hypokalemia, hypomagnesemia, or long QT syndrome.

Tazverik (tazemetostat)(77)

None

Temodar (temozolomide)(78)

Contraindicated in patients with history of serious hypersensitivity to temozolomide or any other ingredients in Temodar and dacarbazine.

Tepmetko (tepotinib)(79)

None

Thalomid (thalidomide)(80)

Thalomid has a boxed warning for embryo-fetal toxicity and venous thromboembolism:

• If Thalomid is taken during pregnancy, it can cause severe birth defects or embryo-fetal death and should never be used by females who are pregnant or who could become pregnant while taking the drug. Even a single dose (regardless of strength) taken by a pregnant woman during her pregnancy can cause severe birth defects.
• The use of Thalomid in multiple myeloma results in an increased risk of venous thromboembolism, such as deep venous thrombosis and pulmonary embolism. This risk increases significantly when Thalomid is used in combination with standard chemotherapeutic agents including dexamethasone. 

Thalomid is available through the Thalomid REMS program approved by the FDA.

Contraindicated in the following:

• Females who are pregnant.
• Patients who have demonstrated hypersensitivity to the drug or its components.

Tibsovo (ivosidenib)(81)

Tibsovo has a boxed warning for differentiation syndrome in AML and MDS:

• Patients treated with Tibsovo have experienced symptoms of differentiation syndrome, which can be fatal. Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, and hepatic, renal, or multi-organ dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.

Tibsovo has no contraindications of use.

Tretinoin capsule(82)

Tretinoin has a boxed warning for embryo-fetal toxicity and differentiation syndrome:

• Tretinoin can cause embryo-fetal loss and malformations when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Females of reproductive potential must have a negative pregnancy test before initiating tretinoin. 
• Differentiation Syndrome, which can be life-threatening or fatal, occurred in about 26% of patients with APL who received tretinoin. At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. Consider withholding tretinoin for moderate and severe Differentiation Syndrome until resolution.  

Contraindicated in patients with known hypersensitivity to tretinoin, any of its components, or other retinoids.

Truqap (capivasertib)(117)

Contraindicated in patients with severe hypersensitivity to Truqap or any of its components.  

Truseltiq (infigratinib)(83)

None

Tukysa (tucatinib)(84)

None

Turalio (pexidartinib)(85)

Turalio has a boxed warning for hepatotoxicity:

• Turalio can cause serious and potentially fatal liver injury. Monitor liver tests prior to initiation of Turalio and at specified intervals during treatment. Withhold and dose reduce or permanently discontinue Turalio based on severity of hepatotoxicity. Turalio is available only through a restricted program called the Turalio REMS Program. 

Turalio has no contraindications of use.

Tykerb (lapatinib)(83)

Tykerb has a boxed warning for hepatotoxicity:

• Hepatotoxicity has been observed in clinical trials and postmarketing experience. The hepatotoxicity may be severe and deaths have been reported. Causality of the deaths is uncertain.

Contraindicated in patients with known hypersensitivity to lapatinib or its components.

Vanflyta (quizartinib)(113)

Vanflyta has a boxed warning for QT prolongation, torsades de pointes, and cardiac arrest:

• Vanflyta prolongs the QT interval in a dose- and concentration-related manner. Prior to Vanflyta administration and periodically, monitor for hypokalemia or hypomagnesemia, and correct deficiencies. Perform ECGs to monitor the QTc at baseline, weekly during induction and consolidation therapy, weekly for at least the first month of maintenance, and periodically thereafter.
• Torsades de pointes and cardiac arrest have occurred in patients receiving Vanflyta. Do not administer Vanflyta to patients with severe hypokalemia, severe hypomagnesemia, or long QT syndrome.
• Do not initiate treatment with Vanflyta or escalate the Vanflyta dose if the QT interval corrected by Fridericia's formula (QTcF) is greater than 450 ms.
• Monitor ECGs more frequently if concomitant use of drugs known to prolong the QT interval is required.
• Reduce the Vanflyta dose when used concomitantly with strong CYP3A inhibitors, as they may increase quizartinib exposure.
• Because of the risk of QT prolongation, Vanflyta is available only through a restricted program under the Vanflyta REMS program.

Contraindicated in patients with severe hypokalemia, severe hypomagnesemia, long QT syndrome, or in patients with a history of ventricular arrhythmias or torsades de pointes.

Venclexta (venetoclax)(88)

Contraindicated in concomitant use with strong CYP3A inhibitors at initiation and during ramp-up phase in patients with CLL/SLL is contraindicated.

Verzenio (abemaciclib)(89)

None

Vitrakvi (larotrectinib)(90)

None

Vizimpro (dacomitinib)(91)

None

Vonjo (pacritinib)(106)

Contraindicated in concomitant use with a strong CYP3A4 inhibitor or inducer.

Voranigo(1)

None

Votrient (pazopanib)(92)

Votrient has a boxed warning for hepatotoxicity:

• Severe and fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended.

Votrient has no contraindications of use.

Welireg (belzutifan)(93)

Welireg has a boxed warning for embryo-fetal toxicity:

• Exposure to Welireg during pregnancy can cause embryo-fetal harm.
• Verify pregnancy status prior to the initiation of Welireg.
• Advise patients of these risks and the need for effective non-hormonal contraception. Welireg can render some hormonal contraceptives ineffective.

Welireg has no contraindications of use.

Xalkori (crizotinib)(94)

None

Xeloda (capecitabine)(95)

Xeloda has a boxed warning for increased risk of bleeding with concomitant use of vitamin K antagonists:

• Altered coagulation parameters and/or bleeding, including death, have been reported in patients taking Xeloda concomitantly with oral vitamin K antagonists, such as warfarin.
• Clinically significant increases in prothrombin time (PT) and international normalized ratio (INR) have been reported in patients who were on stable doses of a vitamin K antagonist at the time Xeloda was introduced. These events occurred within several days and up to several months after initiating Xeloda and, in a few cases, within 1 month after stopping Xeloda. These events occurred in patients with and without liver metastases. Monitor INR more frequently and adjust the dose of the vitamin K antagonist as appropriate.

Contraindicated in patients with a severe hypersensitivity to fluorouracil or capecitabine.

Xospata (gilteritinib)(96)

Xospata has a boxed warning for differentiation syndrome:

• Patients treated with Xospata have experienced symptoms of differentiation syndrome, which can be fatal or life-threatening if not treated. Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, or renal dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.

Contraindicated in patients with hypersensitivity to gilteritinib or any of the excipients.

Xpovio (selinexor)(97)

None

Xtandi (enzalutamide)(98)

None

Yonsa (abiraterone acetate)(99)

None

Zejula (niraparib)(100,112)

None

Zelboraf (vemurafenib)(101)

None

Zolinza (vorinostat)(102)

None

Zydelig (idelalisib)(103)

Zydelig has a boxed warning for fatal and serious toxicities: hepatic, severe diarrhea, colitis, pneumonitis, infections, and intestinal perforation:

• Fatal and/or serious hepatotoxicity occurred in 16% of Zydelig-treated patients. Monitor hepatic function prior to and during treatment. Interrupt and then reduce or discontinue Zydelig as recommended.
• Fatal and/or serious and severe diarrhea or colitis occurred in 20% of Zydelig-treated patients. Monitor for the development of severe diarrhea or colitis. Interrupt and then reduce or discontinue Zydelig as recommended.
• Fatal and/or serious pneumonitis occurred in 4% of Zydelig-treated patients. Monitor for pulmonary symptoms and bilateral interstitial infiltrates. Interrupt or discontinue Zydelig as recommended.
• Fatal and/or serious infections occurred in 48% of Zydelig-treated patients. Monitor for signs and symptoms of infection. Interrupt Zydelig if infection is suspected.
• Fatal and serious intestinal perforation can occur in Zydelig-treated patients across clinical trials. Discontinue Zydelig for intestinal perforation.

Contraindicated in patients with a history of serious allergic reactions to idelalisib, including anaphylaxis and toxic epidermal necrolysis with any drug.

Zykadia (ceritinib)(104)

None

Zytiga (abiraterone)(105)

None